Notably, Shi et al. [124] confirmed the effectiveness of B7-H3 as a therapeutic target in PCa and proposed the use of PTEN/TP53 as a biomarker to guide the use of B7-H3 targeted drugs, thus providing a potential regimen for PCa. This evidence concerns the gene CD276 and posterior cortical atrophy.